| Wednesday 07 | Thursday 08 | Friday 09 | |||
| 1 | POPULATION PHARMACOKINETIC MODELING OF PLASMA AND TISSUE CONCENTRATIONS OF GEMIFLOXACIN IN NON-INFECTED AND S. Pneumoniae INFECTED WISTAR RATS. | 1 | POPULATION PHARMACOKINETICS OF MYCOPHENOLIC ACID IN PATIENTS WITH LUPUS NEPHRITIS. | 1 | PHARMACOKINETICS AND PHARMACOGENETICS OF LAMOTRIGINE IN ADULT PATIENTS WITH EPILEPSY. |
| 2 | PRE-CLINICAL POPPK MODELING AND TISSUE DISTRIBUTION OF RESVERATROL. | 2 | MODELING & SIMULATION OF AMIKACIN IN PEDIATRIC CYSTIC FIBROSIS FOR DOSE OPTIMIZATION. | 2 | WHERE A PHARMACOKINETIC/PHARMACODYNAMIC STUDY BEGIN?. |
| 3 | BIOANALYTICAL METHOD VALIDATION FOR THE SIMULTANEOUS DETERMINATION OF PARACETAMOL, AMANTADINE AND CHLORPHENIRAMINE IN HUMAN PLASMA BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY. | 3 | DETERMINATION OF MYCOPHENOLIC ACID AND PHARMACOKINETIC APPLICATION IN KIDNEY TRANSPLANT PATIENTS. | 3 | THERAPEUTIC DRUG MONITORING OF ISONIAZID AND RIFAMPICIN AND GENOTYPING ANALYSIS IN PATIENTS WITH TUBERCULOSIS. |
| 4 | APPLICATION OF METHOD BY UPLC-MS/MS FOR QUANTIFICATION OF METHOTREXATE POLYGLUTAMATES IN PATIENTS WITH RHEUMATOID ARTHRITIS | 4 | THERAPEUTIC DRUG MONITORING OF LEVETIRACETAM IN PATIENTS WITH EPILEPSY | 4 | Correspondence between the CYP2C19 and CYP3A4 genotypes with the inferred metabolizer phenotype by omeprazole administration in Mexican healthy children |
| 5 | QUANTIFICATION OF LOPERAMIDE IN HUMAN PLASMA BY ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY –MASS SPECTROMETRY. | 5 | PHARMACOKINETICS OF DIGOXIN IN PATIENTS WITH HEART FAILURE AND ARRHYTHMIAS. | 5 | ON THE MONTE CARLO BOOTSTRAP METHOD BASED ON POSTERIOR BAYES PARAMETERS IN POPULATION PHARMACOKINETIC MODELING. |
| 6 | Non linear pharmacokinetics in rats of a galloylquinic acid isolated from Copaifera langsdorffii. | 6 | POPULATION PHARMACOKINETIC MODEL OF LAMOTRIGINE IN MEXICAN CHILDREN WITH EPILEPSY. | 6 | EFFECT OF OLANZAPINE ON INDICATORS OF OXIDATIVE STRESS OF PEOPLE WITH SCHIZOPHRENIA. |
| 7 | BETACYANINS FROM Opuntia robusta AND Opuntia streptacantha FRUITS AGAINST ACETAMINOPHEN-INDUCED OXIDATIVE LIVER DAMAGE. | 7 | UNDERSTANDING THE IMPACT OF ENTERIC REABSORPTION ON DRUG PHARMACOKINETICS. | 7 | PHARMACOKINETICS AND PHARMACOGENETICS OF METHOTAXATE IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA. |
| 8 | QUANTIFICATION OF EFAVIRENZ, EMTRICITABINE AND TENOFOVIR IN PLASMA FROM HIV-POSITIVE PREGNANT WOMEN: ANALYTICAL DEVELOPMENT AND CLINICAL APPLICATION. | 8 | COVARIATES AFFECTING PHENOBARBITAL PHARMACOKINETIC PARAMETERS IN DOGS. | 8 | PHARMACOKINETICS AND PHARMACOGENETICS OF METFORMINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. |
| 9 | PHARMACOKINETIC EVALUATION OF LYOPHILIZED KIT FORMULATIONS FOR THE RADIOLABELING OF MONOCLONAL ANTIBODIES AS THERANOSTIC TOOLS IN NUCLEAR MEDICINE APPLICATIONS. | 9 | EVALUATION OF ANTHELMINTICS COMBINATION USING CAENORHABDITIS ELEGANS AS A MODEL. | 9 | COMPARISON OF TAMOXIFEN AND ENDOXIFEN PLASMA CONCENTRATIONS IN MEXICAN MESTIZO PATIENTS WITH A METABOLIC CYP2D6 AND CYP3A PHENOTYPE PHARMACOKINETIC MODEL. |
| 10 | PHARMACOKINETIC AND EFFICACY EVALUATION OF QUININE-LOADED NANOCAPSULES IN Plasmodium berghei INFECTED RODENTS. | 10 | THERAPEUTIC DRUG MONITORING OF VANCOMYCIN IN PATIENTS OF INTENSIVE CARE UNIT OF INSTITUTO NACIONAL DE NEUROLOGÍA Y NEUROCIRUGÍA. | 10 | SYNTHESIS OF PECA-PCL NANOPARTICLES BY SEMICONTINUOUS HETEREGENEOUS POLYMERIZATION |
| 11 | DEVELOPMENT AND CHARACTERIZATION OF METFORMIN-LOADED PLGA NANOPARTICLES. | 11 | DOG MODEL PREDICT THE BENZNIDAZOLE PHARMACOKINETICS IN CLINICAL TRIALS. | ||
| 12 | BIOEQUIVALENCE OF IVERMECTIN IN COMBINED FORMULATIONS OF IVERMECTIN / FLUAZURON. | 12 | PREDICTIVE PERFORMANCE OF A VANCOMYCIN POPULATION PHARMACOKINETIC MODEL IN MEXICAN PATIENTS. | ||
| 13 | PHARMACOKINETIC OF IVERMECTIN (3.15%) LONG-ACTING FORMULATIONS IN CATTLE. | ||||
| 14 | INFLUENCE OF EXPERIMENTAL CHRONIC Trypanosoma cruzi INFECTION IN THE BENZNIDAZOLE PHARMACOKINETICS IN MICE. | ||||